Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Our portfolio is made up of both patent-protected and off-patent medicines.
GSK is committed to researching and manufacturing innovative medicines for a range of conditions, including respiratory disease, skin conditions and viral infections. Once developed, we aim to make these products as accessible as possible to countries at all levels of income and development.
While GSK’s global pharmaceuticals portfolio covers seven key areas – respiratory, immune-inflammation, infectious disease, cardiovascular, metabolic, dermatology and rare diseases – we are particularly known in New Zealand for our respiratory medicines.
We have invested more in respiratory research than any other company worldwide since the invention of our first asthma treatment in the 1960s.
As a world leader in respiratory disease treatments, we have a portfolio of well-established product. We continue to strengthen and broaden our offerings, with the addition of three new medicines in Australasia to address asthma and COPD last year, and more to come in the future.
Read more about our pharmaceutical business on the global website.